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Key points
 Intramyocellular lipid storage is negatively associated with insulin sensitivity. However, end-
urance trained athletes and type 2 diabetes mellitus (T2DM) patients store similar amounts of
lipids in their muscle; the so-called athlete’s paradox.
 Compared to T2DM, trained athletes possess higher levels of perilipin 5 (PLIN5), a lipid
droplet (LD) coating protein. We examined whether coating LD with PLIN5 affects the pattern
of muscle lipid (LD size and number) in relation to the athlete’s paradox.
 Despite differences in PLIN5 protein content, we observed that coating the LD with PLIN5
could not explain the observed differences in LD size and number between athletes and T2DM.
PLIN5-coated LDs were positively associated with oxidative capacity but not with insulin
sensitivity.
 We conclude that coating of LDs with PLIN5 cannot causally explain the athlete’s paradox.
Abstract Intramyocellular lipid (IMCL) hampers insulin sensitivity, albeit not in endurance-
trained athletes (Trained). Compared to type 2 diabetes mellitus (T2DM) patients, Trained
subjects have high levels of perilipin 5 (PLIN5). In the present study, we tested whether the
fraction of PLIN5-coated lipid droplets (LDs) is a determinant of skeletal muscle insulin sensitivity
and contributes to the athlete’s paradox. Muscle biopsies were taken from eight Trained, Lean
sedentary, Obese and T2DM subjects. Trained, Obese and T2DM subjects were matched for total
IMCL content. Confocal images were analysed for lipid area fraction, LD size and number and
PLIN5+ and PLIN5– LDs were measured. A stepwise linear regression was performed to identify
factors explaining observed variance in glucose infusion rate (GIR). Trained and T2DM subjects
stored IMCL differently; Trained subjects had a higher number of LDs compared to T2DM
subjects (0.037 ± 0.004 µm−2 vs. 0.023 ± 0.003 µm−2, P = 0.024) that were non-significantly
smaller (0.27 ± 0.01 µm2 vs. 0.32 ± 0.02 µm2, P = 0.197, Trained vs. T2DM). Even though
total PLIN5 protein content was almost double in Trained vs. T2DM subjects (1.65 ± 0.21 AU
vs. 0.89 ± 0.09 AU, P = 0.004), PLIN5 coating did not affect LD number or size significantly.
∗These authors contributed equally to this work.
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Of the observed variance in GIR, the largest fraction by far (70.2%) was explained by maximal
oxygen uptake. Adding PLIN5 protein content or PLIN5+ LDs increased the explained variance
in GIR (74.7% and 80.7% for PLIN5 protein content and PLIN5+ LDs, respectively). Thus, the
putative relationship between PLIN5 and insulin sensitivity is at best indirect and is apparent
only in conjunction with maximal oxygen uptake. Hence, PLIN5 abundance cannot be causally
linked to the athlete’s paradox.
(Received 28 August 2017; accepted after revision 25 October 2017; first published online 7 November 2017)
Corresponding author M. K.C. Hesselink: Department of Human Biology and Human Movement Sciences, NUTRIM
School for Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre+, 6200MD
Maastricht, The Netherlands. Email: matthijs.hesselink@maastrichtuniversity.nl
Introduction
Excess storage of fat in skeletal muscle (intramyocellular
lipid; IMCL) associates negatively with insulin sensitivity
(Pan et al. 1997; Krssak et al. 1999; Goodpaster
et al. 2000) but not in endurance trained athletes.
Athletes store IMCL abundantly, at the same time as
maintaining insulin sensitivity, a phenomenon referred
to as ‘the athletes’ paradox’ (Goodpaster et al. 2001).
Experimentally augmenting fat storage by lipid infusion
indeed renders healthy lean subjects’ insulin resistant.
In trained athletes, who can readily shuttle infused
lipids towards oxidation or storage in myocellular liquid
droplets (LDs), lipid-induced insulin resistance is blunted
(Phielix et al. 2012). The composition of skeletal muscle
lipids in master athletes differs from age-matched type 2
diabetes mellitus (T2DM) patients (Amati et al. 2011), an
observation paralleled by higher protein content of the LD
coat protein perilipin 5 (PLIN5) in trained athletes.
PLIN5 is a lipid droplet (LD) coat protein with a putative
role in liberating fatty acids for oxidative degradation in
mitochondria (Wang et al. 2011; Bosma et al. 2012). Using
an in vivo approach, we showed that overexpression of
PLIN5 augmented IMCL content, which predominantly
originates from increased LD size. Despite the increased
IMCL upon PLIN5 overexpression, insulin sensitivity was
maintained (Bosma et al. 2013). In the same model,
we also observed that PLIN5-coated LDs differ in lipid
composition compared to LDs devoid of PLIN5 (Billecke
et al. 2015). This indicates that the abundance of PLIN5 on
myocellular LDs may promote benign (rather than insulin
desensitizing) handling of myocellular fat.
A protective effect of LDs coated with PLIN5 against
lipid-induced insulin resistance was also observed upon
prolonged fasting (Gemmink et al. 2016). With the
application of our custom developed approach to
differentiate LDs coated with PLIN5 (PLIN5+ LDs) from
those devoid of PLIN5 (PLIN5– LDs) in a model of
fasting-induced insulin resistance, we were able to show
that having a high capacity to increase IMCL content at
the same time as maintaining insulin sensitivity originated
from PLIN5+ LDs and not from LDs devoid of PLIN5.
In the present study, we test the hypothesis that, in the
face of similar IMCL content, the fraction of PLIN5+
LDs is a determinant of skeletal muscle insulin sensitivity
(and related parameters) and may help to explain the
athlete’s paradox. Accordingly, we examined subjects
with comparable IMCL content at both extremes of the
spectrum of insulin sensitivity. To span the full spectrum
of insulin sensitivity, subjects with intermediate insulin
sensitivity were also included. Thus, we selected healthy,
lean, insulin sensitive athletes and their body mass index
(BMI)- and age matched non-athletic controls, along with
obese, middle-aged, insulin resistant T2DM patients and
normoglycaemic controls matched for BMI and age.
Methods
Ethical approval
All subjects provided their written informed consent
before participation and were selected from a larger cohort
(Vosselman et al. 2015; Brouwers et al. 2017). These pre-
vious conducted studies were performed in accordance
with the Declaration of Helsinki and were approved by the
Medical Ethic Committee of Maastricht University. This
study was registered at clinicaltrials.gov (NCT01317576).
Subjects
Young male endurance trained subjects (V̇O2max >
55 ml kg−1 min−1) (Trained), lean sedentary subjects
(V̇O2max < 45 ml kg
−1 min−1) (Lean), middle-aged
obese subjects (Obese) and T2DM patients (n = 8 for
each group) participated in the present study. T2DM
patients were on anti-diabetic medication (metformin or
metformin and sulphonylurea derivatives). To investigate
the involvement of the fraction of PLIN5+ LDs in the
athlete’s paradox (high and similar levels of IMCL with
a wide range of insulin sensitivity), we selected Trained,
Obese and T2DM subjects based on having similar IMCL
content after staining muscle biopsy sections with Bodipy
493/503 (Molecular Probes, Leiden, The Netherlands) and
quantifying the area fraction covered by LDs. Samples
C© 2017 The Authors. The Journal of Physiology C© 2017 The Physiological Society
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of poor histological quality were discarded. Lean sub-
jects were randomly selected from the same cohort as the
Trained. Thus, eight subjects were included in all four
groups.
A muscle biopsy was taken from the musculus
vastus lateralis just prior to measuring insulin sensitivity
by a two-step hyperinsulinaemic-euglycaemic clamp
performed essentially as described by Brouwers et al.
(2017). In brief, insulin sensitivity is presented as
the glucose infusion rate (GIR) required to maintain
euglycaemia during the second (high insulin) step of
the clamp, hence predominantly reflecting peripheral
(muscle) insulin sensitivity. A part of the muscle
biopsy was processed for histochemical and western blot
analysis. Another portion was placed in ice-cold modified
SET-buffer (250 nM sucrose, 10 mM Tris-HCl, 1 mM
EDTA and 2 mM ATP) to measure ex vivo 14C palmitate
oxidation. Maximal oxidative capacity was measured
with a graded maximal cycle test. Oxygen consumption
was measured throughout the test (Omnical, Maastricht,
The Netherlands). Furthermore, body composition was
measured with dual X-ray absorptiometry (Hologic
Discovery A, Waltham, MA, USA) and fasting plasma
glucose was determined with an enzymatic assay on
a Cobas Fara/Mira (Roche, Basel, Switzerland) via the
hexokinase method.
Histochemical analysis
For immunofluorescence analysis of IMCL content, LD
size, LD number and PLIN5, we cut 7 µm thick
cryosections. Sections were stained as described previously
(Gemmink et al. 2016).
To assess muscle fibre type distribution, based on
myosin heavy chain type I immunofluorescence staining
essentially as described by Koopman et al. (2001) with
the exception of the primary antibody used in the pre-
sent study (A4.840; Dev. Hybr. Bank, Iowa, USA), and to
assess IMCL content (Bodipy 493/503; Molecular Probes)
to facilitate selection of subjects with similar IMCL levels,
images were taken using a Nikon E800 fluorescence micro-
scope (Nikon, Amsterdam, The Netherlands) coupled to a
Nikon DS-Fi1c colour CCD camera (Nikon). The relative
fraction of type I and type II muscle fibres was individually
determined using ImageJ (NIH, Bethesda, MD, USA)
(Schneider et al. 2012). Analysis of LD area fraction,
LD number and LD size was performed as described
previously (Gemmink et al. 2016). Full morphometric
analysis was performed for 5533 ± 1064, 1876 ± 439,
2166 ± 529 and 3244 ± 474 LDs for Trained, Lean, Obese
and T2DM subjects, respectively. After deconvolution
using Huygens Essential software (Scientific Volume
Imaging BV, Hilversum, The Netherlands), images were
analysed for LD size and number with ImageJ. Although
PLIN5 has originally been described as a LD coat protein,
PLIN5, the original study also describes PLIN5 in cytosolic
fractions (Wolins et al. 2006). In line with this, we recently
observed that prolonged fasting resulted in a redistribution
of PLIN5 from cytosolic pools to the LD (Gemmink et al.
2016), suggesting that PLIN5 motility may have physio-
logical implications. Hence, we also applied our novel
microscopy approach to dissect PLIN5+ from PLIN5–
LDs in the present study. Thus, LDs were subdivided into
PLIN5 positive LDs (PLIN5+) and LDs devoid of PLIN5
(PLIN5–) using custom-made computer software written
in MatlabR2013a (Mathworks, Natick, MA, USA).
Western blotting
For western blot analysis, an antibody against PLIN5
(GP31; Progen Biotechnik, Heidelberg, Germany)
was used. Near infra-red tagged secondary antibody
(IRDye; LI-COR Biosciences, Westburg, Leusden, The
Netherlands) was used to visualize and quantify the
appropriate band (Odyssey Infrared Imaging system;
LI-COR Biosciences).
14C palmitate oxidation assay
Fresh muscle biopsy material was homogenized in ice-cold
SET buffer and 80 µl of this was loaded into a modified
48 well device in triplicate. Reactions were initiated with
the addition of working buffer [0.2 mM palmitate and
1 µCi ml−1 [1-14C]-palmitate (NEC075H250UC; Perkin
Elmer Nederland BV, Groningen, The Netherlands), 7.5%
fatty acid free bovine serum albumin 100 mM KCl, 62.5 mM
sucrose, 12.5 mM KH2PO4, 10 mM Tris-HCl, 2 mM ATP,
1.25 mM MgCl, 1.25 mM L-carnitine, 1.25 mM DTT,
0.125 mM malic acid, 0.125 mM NAD+ and 0.0625 mM
coenzyme A]. The device was incubated for 2 h at 37°C.
Reactions were terminated with the addition of 40 µl
of 70% perchloric acid. The device was transferred to a
shaking table and incubated for 1 h at room temperature.
The released CO2 was trapped in 1 M NaOH in the
adjacent well. Subsequently, 200 µl of NaOH containing
the trapped CO2 was transferred to a scintillation vial with
OptiFluor scintillation fluid. Radioactivity was counted on
a Tri-Carb 2910 TR Liquid Scintillation Analyser (Perkin
Elmer Nederland BV).
Statistical analysis
The results are reported as the mean ± SEM. Statistical
analysis were performed using SPSS, version 21.0 (IBM
Corp., Armonk, NY, USA). A one-way ANOVA with a
Bonferroni post hoc test was used to test for statistical
differences between groups for subject characteristics,
total IMCL content, LD area fraction, LD size and LD
number of all LDs, and PLIN5 protein content. Upon
distinction between PLIN5+ and PLIN5– LDs, statistical
C© 2017 The Authors. The Journal of Physiology C© 2017 The Physiological Society
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Table 1. Subject characteristics
Parameter Athletes Untrained Obese T2DM
Age (years) 26.0 ± 1.8 23.5 ± 1.2 54.1 ± 3.1∗† 60.6 ± 2.0∗†
Body weight (kg) 72.4 ± 2.6 73.1 ± 2.3 96.1 ± 3.3∗† 95.9 ± 2.8∗†
Lean body mass (kg) 60.8 ± 2.2 57.1 ± 1.9 68.8 ± 3.0† 69.2 ± 2.0†
% Fat mass 13.4 ± 0.5 18.4 ± 1.5∗ 28.9 ± 0.9∗† 28.3 ± 0.9∗†
BMI (kg m−2) 21.0 ± 0.6 22.2 ± 0.6 29.4 ± 0.4∗† 29.6 ± 0.8∗†
Fasting glucose (mmol L−1) 5.14 ± 0.09 5.24 ± 0.10 4.91 ± 0.28 7.43 ± 0.53∗†‡
V̇O2max (ml O2/kg lean mass min
−1) 71.0 ± 1.62 51.8 ± 1.70∗ 39.8 ± 1.93∗† 36.8 ± 1.45∗†
14C palmitate oxidation (nmol/2 h mg−1) 0.22 ± 0.03 0.13 ± 0.02∗ 0.08 ± 0.02∗ 0.08 ± 0.02∗
GIR (µmol kg lean mass−1 min−1) 93.76 ± 6.57 70.36 ± 5.72∗ 37.99 ± 2.85∗† 25.67 ± 2.59∗†
IMCL (%) 3.49 ± 0.69 1.31 ± 0.43 2.77 ± 0.82 2.48 ± 0.29
∗vs. Trained; †vs. Lean; ‡vs. Obese.
differences between groups was tested with a mixed
model ANOVA with PLIN5 (PLIN5+ vs. PLIN5– LDs)
as a within subject factor. When a significant interaction
or main effect was detected, a LSD post hoc test was
performed. Pearson’s correlation coefficients were used to
test for significant linear association between variables.
Using stepwise multiple linear regression analysis, we
examined whether PLIN5 protein content or the number
of PLIN5-coated LDs explained a part of the variance
in insulin sensitivity (GIR) that was not explained by
maximal oxygen uptake (V̇O2max). P < 0.05 was considered
to be statistically significant.
Results
Subject characteristics
Subject characteristics are shown in Table 1. Obese and
T2DM subjects were significantly older than Trained
and Lean subjects. Fat mass was highest in the Obese
and T2DM subjects and lowest in Trained subjects. By
design, patients with T2DM had higher fasting plasma
glucose levels and lower GIR (Table 1) compared to the
other groups. V̇O2max and fatty acid oxidative capacity were
highest in Trained subjects and lowest in T2DM subjects.
Muscle fat content
We selected Trained, Obese and T2DM patients (n = 8
for each group) with similar IMCL content based on
widefield microscopy quantification of the Bodipy signal
(Table 1). These subjects were included for detailed LD
analysis by confocal microscopy. Examination of fibre type
distribution in sections of these subjects (123 ± 12 cells)
revealed that the fraction of type I muscle fibres was higher
in Trained subjects compared to any of the other groups,
albeit non-significantly (59% vs. 42%, 43% and 45% for
Trained, Lean, Obese and T2DM, respectively; P = 0.037).
Detailed LD analysis performed by confocal microscopy
in a selection of muscle cells representing the fibre type
distribution of the individual revealed that, as targeted,
the lipid area fraction in T2DM was not significantly
different from the lipid area fraction in Trained sub-
jects (0.95 ± 0.07% and 0.73 ± 0.13 for Trained and
T2DM, respectively; P=0.818) (Fig. 1A). Maximal aerobic
capacity correlated positively with lipid area fraction
(r = 0.530; P = 0.003) (Fig. 1B). Although the total lipid
area fraction was similar in Trained and T2DM subjects,
Trained subjects had significantly more LDs than T2DM
subjects (0.037 ± 0.004 µm−2 vs. 0.023 ± 0.003 µm−2
for Trained and T2DM, respectively; P = 0.024) (Fig. 1C).
In T2DM subjects, the high lipid area fraction resulted
from non-significantly more LDs (0.020 ± 0.004 µm−2
and 0.017 ± 0.002 µm−2 for, respectively, Lean and
Obese; P > 0.05 vs. T2DM) (Fig. 1C) and larger LDs
(0.27 ± 0.01 µm2, 0.26 ± 0.02 µm2, 0.26 ± 0.02 µm2 and
0.32 ± 0.03 µm2 for, respectively, Trained, Lean, Obese
and T2DM; P = 0.197) (Fig. 1D). The tight correlation
between V̇O2max and LD number (r = 0.659; P < 0.001)
(Fig. 1E) but not size (r = −0.185; P = 0.336) (Fig. 1F)
suggests that, within these groups, maximal oxidative
capacity is associated with LD number rather than
LD size.
PLIN5-associated muscle fat content and insulin
sensitivity
Western blot analysis revealed that PLIN5 protein content
was significantly higher in Trained subjects compared
to any of the other groups (Fig. 2B). Upon making the
distinction between PLIN5+ LDs and PLIN5– LDs, the
lipid area fraction of PLIN5+, as well as the PLIN5–
LDs (Fig. 2C), mirrored the pattern observed for lipid
area fraction of all LDs (Fig. 1A). Representative confocal
images of PLIN5, Bodipy and Laminin are shown in
Fig. 2A. PLIN5+ lipid area fraction in Trained subjects
was significantly higher compared to the other groups
C© 2017 The Authors. The Journal of Physiology C© 2017 The Physiological Society
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(0.79±0.07% for Trained and 0.43±0.11%, 0.34±0.04%
and 0.53 ± 0.10% for Lean, Obese and T2DM, respectively,
P < 0.05). In addition, the PLIN5+ lipid area fraction was
higher than the PLIN5– lipid area fraction in all groups
(Fig. 2C) and appeared to originate predominantly from
more LDs and also larger LDs (Fig. 2D and E) in the
PLIN5+ LDs compared to the PLIN5– LDs. The pattern
observed for LD area fraction, number or size, upon
making the distinction between PLIN5+ and PLIN5– LDs,
was similar to that observed upon simply examining all
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Figure 1. Lipid droplet characteristics and its association with maximal oxygen uptake
A, lipid area fraction measured by confocal microscopy. B, V̇ O2max correlates with lipid area fraction. C,
quantification of number of LDs and (D) LD size. Correlations between V̇ O2max and (E) LD number (F) and LD
size. Circles: Trained; squares: Lean; triangles: Obese; diamonds: T2DM. ∗P < 0.05 compared to Trained subjects.
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LDs, irrespective of their coating with PLIN5. It should
be noted, however, that the fraction of PLIN5+ LDs
(relative to the total number of LDs) was somewhat
(albeit non-significantly P = 0.182) lower in T2DM sub-
jects compared to any of the other groups (0.77 ± 0.03,
0.73 ± 0.05, 0.74 ± 0.05 and 0.64 ± 0.04 for, respectively,
Trained, Lean, Obese and T2DM) (Fig. 2F).
In rodent models (Bosma et al. 2013; Mason et al.
2014), as well as in fasting-mediated lipid-related
insulin resistance in humans (Gemmink et al. 2016),
a protective role for PLIN5 in maintaining peripheral
insulin sensitivity has been shown. Thus, we investigated
whether LD size or number and the coating of the LDs
with PLIN5 was related to peripheral insulin sensitivity.
PLIN5 protein content as assessed by western blotting did
not correlate with insulin sensitivity (measured as GIR,
r = 0.259; P = 0.166) (Fig. 3A). Markers of muscle lipid
content (lipid area fraction, LD number or LD size) also
did not consistently correlate with insulin sensitivity upon
making the distinction between PLIN5+ and PLIN5– LDs
(Fig. 3B–G). Thus, in the groups investigated in the pre-
sent study, coating of the LD with PLIN5 per se does not
appear to affect insulin sensitivity.
PLIN5-coated LDs and oxidative capacity
PLIN5 protein content as assessed by western blotting
correlated positively with V̇O2max (r = 0.520; P = 0.005)
(Fig. 4A). The correlations between V̇O2max and lipid area
fraction (Fig. 1B) and LD number (Fig. 1E) were revealed
to be driven by PLIN5+ LDs (r = 0.600; P = 0.001 for
V̇O2max and lipid area fraction and r = 0.695; P < 0.001
Trained Lean Obese T2DM
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for V̇O2max and LD number for PLIN5+ LDs) (Fig. 4B
and C) but not by PLIN5– LDs (Fig. 4D and E). The
correlation between V̇O2max and PLIN5 content was absent
(r = –0.222; P = 0.334) when Trained subjects were
excluded from the correlation.
The observation that correlations between maximal
oxidative capacity and markers of muscle lipid fat content
relate to PLIN5+ (and not PLIN5–) LDs is interesting
in light of previous observations indicating that PLIN5
protein content is high in tissues with a high oxidative
capacity and triggered an examination of the putative
association of PLIN5 coating with the ex vivo ability to
oxidize palmitate. Total lipid area fraction and total PLIN5
content in cell lysates correlated positively with the ex
vivo capacity to oxidize palmitate (r = 0.385; P = 0.033
and r = 0.362; P = 0.049, respectively) (Fig. 5A and
B). The association between lipid area fraction and ex
vivo palmitate oxidative capacity could be attributed to
PLIN5+ but not PLIN5– LDs (r = 0.390; P = 0.030 and
r = 0.227; P = 0.219, respectively) (Fig. 5C and D).
Stepwise multiple regression analysis
Although linear regression analysis revealed no direct
correlations of insulin sensitivity with PLIN5 content
or PLIN5+ LDs, insulin sensitivity did correlate with
V̇O2max, explaining 70.2% of the observed variance in GIR
(r = 0.838, r2 = 0.702 and P < 0.001). Given the suggested
role of PLIN5 in modulating oxidative lipolysis (Wang et al.
2011), we investigated whether PLIN5 protein content or
number of PLIN5+ and PLIN5– LDs could add to the
observed unexplained variance in GIR. This revealed that
PLIN5 protein content together with V̇O2max explained
74.7% of the observed variance in insulin sensitivity
(r2 = 0.747; P < 0.001) (Table 2). Similarly, inclusion of the
number of PLIN5+ LDs increased the explained variance
in GIR to 80.7% (r2 = 0.807; P < 0.001) (Table 2). Overall,
this may indicate a role for PLIN5 in modulating insulin
sensitivity in conjunction with oxidative capacity.
Discussion
Given previous observations of PLIN5 being a LD coat
protein favouring benign IMCL storage, we hypothesized
that, with similar IMCL content, the fraction of PLIN5+
LDs was a determinant of skeletal muscle insulin sensitivity
and a contributing factor to the athlete’s paradox. With
similar IMCL content, PLIN5 protein content and insulin
sensitivity were significantly higher in Trained subjects
compared to T2DM subjects. A straightforward inter-
pretation of this would be that having high PLIN5 levels
is indeed paralleled by high peripheral insulin sensitivity.
However, PLIN5 levels measured by western blotting did
not correlate with peripheral insulin sensitivity. Upon
P
L
IN
5
p
ro
te
in
(A
U
)
P
L
IN
5
 −
 L
ip
id
 A
re
a
 F
ra
c
ti
o
n
 (
%
)
P
L
IN
5
+
L
ip
i d
A
r e
a
F
ra
ct
io
n
(%
)
P
L
I N
5
+
L
D
n
o
.
(L
D
s/
µm
2
)
P
L
IN
5
−
L
D
n
o
.
(L
D
s/
µm
2
)
A B C
3 1.0
0.040
2
1
r = 0.468
p = 0.012
0
0.8
0.6
0.4
0.2
0.0
r = 0.600
p = 0.001
0.030
0.020
0.010
0.000
r = 0.695
p < 0.001
0 20 40 60 80 100
VO2max (ml/kg lean body mass/min) VO2max (ml/kg lean body mass/min) VO2max (ml/kg lean body mass/min)
VO2max (ml/kg lean body mass/min) VO2max (ml/kg lean body mass/min)
0 20 40 60 80 100 0 20 40 60 80 100
D E
0.3
0.015
0.2 0.010
0.1
0.0
r = 0.055
p = 0.776
0.005
0.000
r = 0.247
p = 0.197 Trained Lean 0bese T2DM
0 20 40 60 80 100 0 20 40 60 80 100
Figure 4. PLIN5 and whole body oxidative capacity
Correlations between V̇ O2max and (A) PLIN5 protein content, (B) PLIN5– lipid area fraction, (C) PLIN5+ lipid area
fraction, (D) PLIN5– LD number and (E) PLIN5+ LD number. Circles: Trained; squares: Lean; triangles: Obese;
diamonds: T2DM.
C© 2017 The Authors. The Journal of Physiology C© 2017 The Physiological Society
J Physiol 596.5 PLIN5 and insulin sensitivity in trained and type 2 diabetes 865
Table 2. Stepwise multiple linear regression
Dependent Input variables Significant correlates r2 P
GIR V̇O2max, PLIN5 protein content V̇O2max, PLIN5 protein content 0.747 < 0.001
GIR V̇O2max, PLIN5+ LD number,
PLIN5– LD number
V̇O2max number PLIN5+ LD 0.803 < 0.001
making the distinction between PLIN5+ and PLIN5– LDs,
we observed that the lipid area fraction of PLIN5+ LDs
was higher in the highly insulin sensitive Trained sub-
jects compared to any of the other groups. Moreover,
Trained subjects had significantly more PLIN5+ LDs
than any of the other groups, whereas LD size was
similar across groups. By contrast to expectations, we
did not detect a correlation between the number of
PLIN5+ LDs and insulin sensitivity using univariate
linear regression analysis. Associative data from stepwise
multiple regression analysis suggest that PLIN5 protein
levels and also the number of PLIN5+ LDs explained a
part of the variance observed in GIR that was not explained
by V̇O2max. In addition, the ability to oxidize fatty acids
correlates positively with PLIN5-coated IMCL. This led us
to conclude that total PLIN5 protein levels, as well as the
number of PLIN5+ LDs, only indirectly affect to paradox
of having high insulin sensitivity in conjunction with high
levels of IMCL in the trained athletes.
In experimental models, the overexpression of PLIN5
promoted oxidative gene expression and mitochondrial
LD interaction (Bosma et al. 2013). In humans, PLIN5
protein content has been associated with a high oxidative
capacity (Amati et al. 2011; Koves et al. 2013) and
endurance training up-regulates PLIN5 protein content
(Peters et al. 2012; Louche et al. 2013; Shepherd et al.
2013). Conversely, 2 weeks of immobilization resulted in
a drop in PLIN5 levels and markers of oxidative capacity
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(Vigelso et al. 2016). Upon differentiation between
PLIN5+ and PLIN5– LDs, we observed that more LDs
were coated with PLIN5 and these PLIN5-coated LDs
were larger in size than LDs devoid of PLIN5. This
observation was made in all four groups. The number
of LDs associated with PLIN5 increases upon exercise
training (Shepherd et al. 2013). This is in accordance with
our findings showing that the number of PLIN5+ LDs
in Trained subjects is almost double that in Lean, Obese
or T2DM subjects. Interestingly, we observed that PLIN5
protein content and the lipid area fraction of muscle
covered by PLIN5+ LDs, as well as the number of PLIN5+
LDs, all correlate positively with V̇O2max, whereas this
correlation was absent for PLIN5– LDs. Remarkably, the
correlation between V̇O2max and PLIN5 protein content
measured in muscle cell lysates was absent (or rather
negative) when Trained subjects were excluded from
the correlation. For LDs coated with PLIN5 (PLIN5+
LDs), this correlation was maintained. The significance
of PLIN5+ LDs, relative to total PLIN5 content in cell
lysates, has previously been reported in human models of
insulin resistance when plasma fatty acids were elevated
physiologically upon fasting (Gemmink et al. 2016) or
experimentally by lipid-infusions (Shepherd et al. 2017).
Thus, a high maximal oxidative capacity, a recognized
determinant of insulin sensitivity (Tonino, 1989; Bruce
et al. 2003), coincides with a high fraction of PLIN5+ LDs.
In human primary myotubes, PLIN5 has been suggested
to sequester fatty acids under basal conditions and to
facilitate mitochondrial fat oxidation upon increased
metabolic demand (i.e. stimulated lipolysis) (Laurens et al.
2016). Furthermore, PLIN5 protein content is associated
with mitochondrial fat oxidative capacity and PLIN5 over-
expression results in a more efficient fatty acid oxidation
(Bosma et al. 2012). This matches our results indicating
that PLIN5 levels correlate with the ex vivo capacity to
oxidize fatty acids.
The link between PLIN5 and fat oxidative capacity may
have a dual origin. PLIN5 may be involved in the release of
fatty acids from the LD as ligands for PPAR-mediated
gene expression and hence facilitate the induction of
oxidative genes, with an increased fat oxidative capacity
as a consequence (Bosma et al. 2013). On the other hand,
by promoting the interaction of ATGL and CGI-58 on the
LD, PLIN5 is assumed to control LD lipolysis (Wang et al.
2011), possibly with the aim of tuning the lipolytic rate
to the rate of fat oxidation (Granneman et al. 2009). Our
observation that the lipid area covered by PLIN5+ LDs
correlates positively with ex vivo palmitate oxidation in
lysates emphasizes the notion that PLIN5 at the LD, rather
than cytosolic PLIN5, is of importance with respect to the
fine tuning of LD lipolysis with fat oxidation.
In trained athletes, PLIN5 levels predict insulin
sensitivity (Koves et al. 2013) and whole body PLIN5
deletion results in insulin resistance (Mason et al. 2014),
suggesting a link (directly or indirectly) between PLIN5
and insulin sensitivity. Indeed, we observed higher levels
of PLIN5 in Trained subjects compared to Lean, Obese
or T2DM subjects, as reported in other studies (Amati
et al. 2011; Koves et al. 2013; Vigelso et al. 2016). By
contrast to previous work (Koves et al. 2013; Shepherd et al.
2013; Laurens et al. 2016), however, we did not observe
a direct association between PLIN5 protein content and
insulin sensitivity. Instead, stepwise regression revealed
that maximal oxygen uptake (V̇O2max) explained most of
the variation (70.2%) in insulin sensitivity (GIR) and that
total PLIN5 content in lysates (74.7%) or PLIN5+ LDs
(80.7%) only modestly increased the percentage variance
that was explained.
The present study was designed to include subjects
with a wide range of insulin sensitivity and a minimal
range in muscle fat content. For the high end of the
insulin sensitivity spectrum, we included trained athletes;
for the low end of the insulin sensitivity spectrum, we
included patients with T2DM. Typically, T2DM patients
are middle-aged and overweight to obese, whereas trained
athletes typically are young and lean. Thus, fatness can bias
the outcome of the present study. Hence, we also included
untrained normoglycaemic controls of a similar age and
BMI as the Trained subjects and normoglycaemic sub-
jects of similar BMI, age and maximal oxygen uptake as
the T2DM subjects. For maximal oxygen uptake capacity
and for insulin sensitivity, lean body mass, rather than
total body mass, is the major determinant. Thus, to
permit comparisons between the groups despite a range
in BMI, we present data normalized to lean body mass.
For age, matters become more complicated. The effect of
age on IMCL and/or LD morphology is not unequivocal,
especially so when the effect of an age-related decline
in physical activity is taken into account. Thus, higher
levels of IMCL have been reported in old vs. young,
with LDs being larger in the elderly (Crane et al. 2010);
however, if older and younger subjects were matched
for habitual physical activity, no such differences were
found (Chee et al. 2016), suggesting that age per se is
possibly not driving the outcome of the present study.
Our unique microscopy-based approach permits the
distinction between PLIN5+ and PLIN5– LDs, which we
(Gemmink et al. 2016) and others (Shepherd et al. 2017)
previously reported to provide relevant new insights into
how LDs may affect muscle (patho)physiology. We started
out by assessing muscle fibre type distribution of the
complete section and subsequently performed the detailed
LD analysis in the same fibre type ratio as that assessed in
the complete section. Thus, our data are well representative
of the mixed fibre type in human vastus lateralis muscle
and permit valid comparison between trained athletes and
the other groups.
In conclusion, we demonstrate that an abundance of
PLIN5 in the skeletal muscle of trained athletes relative to
C© 2017 The Authors. The Journal of Physiology C© 2017 The Physiological Society
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patients with T2DM cannot explain the athlete’s paradox
in a direct and straightforward manner. Nevertheless, the
coating of LDs with PLIN5 is observed in parallel with
other favourable contributors to insulin sensitivity, such
as a high whole body oxidative capacity and a good fatty
acid oxidation capacity.
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